Zydus Cadila gets tentative nod from USFDA to market Parkinson’s disease drug

Drugs
(Representative image)
(Consultant picture)

Drug agency Zydus Cadila on Saturday stated it has obtained tentative nod from the US health regulator to market Carbidopa and Levodopa extended-release capsules, used for the therapy of signs of Parkinson’s disease, within the US market.

The corporate has obtained tentative approval from the US Meals and Drug Administration (USFDA) to market the capsules within the strengths of 23.75 mg/95 mg, 36.25 mg/145 mg, 48.75 mg/195 mg, and 61.25 mg/245 mg, Zydus Cadila stated in a press release.

The drug will probably be manufactured on the group’s formulation manufacturing facility at SEZ, Ahmedabad, it added.

This treatment is used to deal with the signs of Parkinson’s disease resembling shakiness, stiffness, problem transferring or Parkinson-like situations, Zydus Cadila stated.

The group now has 295 approvals and has up to now filed over 390 abbreviated new drug purposes (ANDAs) because the graduation of its submitting course of, it added.

Products You May Like

Articles You May Like

Voiceitt raises $10M in a Series A funding round
IIT-Guwahati, RR Animal Healthcare make headway in indigenous Covid-19 kits commercialisation
Can a plant-based diet affect blood pressure?
Experimental COVID-19 vaccine prevents severe disease in mice
LGBTQ youth experience mental health benefits from social media break

Leave a Reply

Your email address will not be published. Required fields are marked *